# OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)

> **NCT01916785** · PHASE2 · COMPLETED · sponsor: **Versailles Hospital** · enrollment: 289 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia, BCR/ABL Positive

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01916785
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2016-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916785, "OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01916785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*